TL;DR:
- HAGAR secures $5 million Series C funding for its GWave non-invasive glucose monitoring system.
- Total funding for HAGAR now stands at an impressive $25 million.
- GWave utilizes unique RF wave technology for real-time, precise blood glucose monitoring.
- The technology focuses directly on blood, enhancing accuracy compared to interstitial fluid measurements.
- Seamless Bluetooth and smartphone integration simplify glucose level tracking.
- An automated alert system notifies users of significant glucose changes.
- A recent study highlights GWave’s accuracy, achieving a mean MARD of 6.7%.
- Hypoglycemic test underscores GWave’s precision in monitoring glucose fluctuations.
- HAGAR aims to integrate GWave technology into smartwatches for global accessibility.
- The technology’s applications extend beyond diabetes to health optimization and chronic illness prevention.
- FDA’s Breakthrough Device Designation boosts HAGAR’s profile and future studies.
- Collaboration with Jaeb Center for Health Research marks strategic direction for future research.
Main AI News:
In a significant stride towards advancing healthcare technology, HAGAR, the visionary force behind GWave, an innovative non-invasive continuous glucose monitoring system, has triumphantly secured a substantial $5 million in its Series C funding round. This achievement elevates the startup’s cumulative funding to an impressive $25 million. The recent highpoint for HAGAR came with the unveiling of its cutting-edge clinical revelations, presented at the esteemed 83rd Scientific Sessions hosted by the American Diabetes Association (ADA).
GWave, the flagship creation of HAGAR, employs an ingenious RF (radio frequency) wave mechanism to enable real-time and precision-based monitoring of blood glucose levels. Unlike its counterparts that gauge glucose concentrations in the interstitial fluid, GWave directly targets blood samples, thereby assuring a significantly higher degree of accuracy. The innovation is further amplified through seamless integration with Bluetooth and smartphones, empowering users to effortlessly track their glucose levels. A standout attribute of GWave is its automated alert system, which promptly notifies users in the event of noteworthy fluctuations in their glucose readings.
The recent breakthrough study, spearheaded by the accomplished Professor Ami Navon from the prestigious Weizmann Institute of Science, engaged a diverse cohort of 75 participants encompassing various age groups, genders, and ethnicities. Among them, 34 individuals were living with diabetes (comprising an impressive 82% with Type I diabetes), alongside ten expectant mothers dealing with diabetes and 31 non-diabetic participants. The study placed a spotlight on GWave’s accuracy, particularly during a rigorous glucose challenge. Impressively, the device exhibited an average MARD (Mean Absolute Relative Difference) of 6.7%, with a staggering 97% of readings falling within Zone A and a mere 3% in Zone B, as per the revered Clarke Error Grid.
Adding to the array of evidence substantiating GWave’s precision, an insightful hypoglycemic test featuring Dr. Irl Hirsch and his distinguished brother, James Hirsch, a renowned journalist and author, further underscored the system’s unwavering accuracy. Throughout a fluctuation in Dr. Hirsch’s glucose levels from 180 to 46, GWave consistently provided dependable monitoring.
HAGAR’s ongoing pursuit of scientific inquiry is primarily geared toward spotlighting GWave’s unparalleled accuracy and operational efficiency. The ultimate aspiration rests in integrating this groundbreaking technology into smartwatches, thereby rendering it affordable and globally accessible. It is noteworthy that the precision of this device extends its potential benefits beyond the diabetic community, encompassing health optimization and the proactive prevention of chronic illnesses.
With its distinction as a Breakthrough Device, as designated by the FDA in 2021, HAGAR’s strategic roadmap includes an extensive array of forthcoming studies slated for both the United States and Israel in the latter half of 2023. This collaborative endeavor will see the involvement of Dr. Roy Beck from the esteemed Jaeb Center for Health Research.
HAGAR’s preceding funding endeavor materialized in the form of a Series B round led by Columbia Pacific in August 2021, wherein the startup successfully garnered an impressive $11.7 million.
Conclusion:
The successful $5 million investment secured by HAGAR for its GWave glucose monitoring system marks a significant milestone in the healthcare technology sector. This achievement demonstrates strong market confidence in the potential of non-invasive, accurate glucose monitoring. The integration of RF wave technology and the pursuit of smartwatch integration showcase HAGAR’s commitment to advancing health monitoring solutions. As the company positions itself for further studies and collaborations, the market can anticipate an evolution towards more accessible and precise glucose monitoring, with far-reaching applications in health optimization and chronic disease prevention.
